Dose escalation/dose expansion study to assess the MTD, safety, tolerability, PK and preliminary anti-tumor activity of RLY-1971. Approximately 50 patients.
Dose escalation/dose expansion study to assess the MTD, safety, tolerability, PK and preliminary anti-tumor activity of RLY-1971. Approximately 50 patients.
NCT04252339
Relay Therapeutics, Inc.
19 February 2024
Congrats! You have your own personal workspace now.